Market Cap (In KRW)
276.4 Billion
Revenue (In KRW)
80.99 Billion
Net Income (In KRW)
25.68 Billion
Avg. Volume
3.49 Million
- Currency
- KRW
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 3325.0-9410.0
- PE
- -
- EPS
- -
- Beta Value
- 0.912
- ISIN
- KR7256840000
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Mr. Wan-Gyu Choi
- Employee Count
- -
- Website
- https://www.bnckorea.co.kr
- Ipo Date
- 2019-11-18
- Details
- BNC Korea Co., Ltd. engages in the research and development, production, and sale of biomaterials in South Korea. The company offers HA fillers and skin booster fillers, including Cutegel, Cutegel Lidocaine, FLORE Lidocaine, ChungA-an, CUTEGEL-M, Cutegel Hydro, S-DNA, and H-DNA, which are used to temporarily reduce facial wrinkles through physical restoration. It also provides Hibarry, a dressing for deep-cavity wounds that is used to reduce adhesion of the spinal cord during surgery; GENTA Q, a white collagen sponge, which is used to protect wounds by preventing contamination of wounds; and beauty solutions, face mask gels, mils cleansing foams, and brightening peeling gels. The company also exports its products to 45 countries. BNC Korea Co., Ltd. was founded in 2007 and is headquartered in Daegu, South Korea.
More Stocks
-
SBTOeneo SA
SBT
-
348370Enchem Co., Ltd.
348370
-
CHEMFABChemfab Alkalis Limited
CHEMFAB
-
SSLLFSiltronic AG
SSLLF
-
QUESSQuess Corp Limited
QUESS
-
603616
-
004700Chokwang Leather Co.,Ltd.
004700
-
AKSHARAkshar Spintex Limited
AKSHAR